NCT00765921View on ClinicalTrials.gov

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 29, 2016

Study Completion Date

September 30, 2016

Conditions
Choroidal Melanoma
Interventions
DRUG

ranibizumab

Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).

Trial Locations (1)

02114

Massachusetts Eye & Ear Infirmary, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts Eye and Ear Infirmary

OTHER